Three months into its U.S. launch for lupus nephritis (LN), Roche/Genentech’s Gazyva (obinutuzumab) is entering a treatment landscape shaped not only by approved agents Benlysta (belimumab, GSK) and ...

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...

Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper ...

Patients with systemic lupus erythematosus who receive belimumab monotherapy show comparable remission rates and disease control to those who receive combination therapy with immunosuppressants.

Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2 trial for discoid lupus ...

Feb 3 (Reuters) - AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an ...

A promising clinical trial underway at UCI Health is aimed at helping patients achieve long-term remission.

A third-year UVA student channels her experience with chronic illness into a drive to strengthen communities through design.

This Black History Month, we’re centering the voices, stories, and experiences of Black lupus warriors. Throughout February, we’re sharing resources and community spaces designed to support and ...